CLAIMS

1. A peptide, or derivative thereof, having an amino acid sequence with a length equal to or lower than 30 amino acids, and comprising any one of SEQ ID Nos. 2, 3, 9, 10, 13, 14, 15, 16, 17, 18, or a conservative variant thereof, for use as a medicament.

2. Use of a peptide, or derivative thereof, having an amino acid sequence with a length equal to or lower than 30 amino acids, and comprising any one of SEQ ID Nos. 2, 3, 9, 10, 13, 14, 15, 16, 17, 18, or a conservative variant thereof, in the manufacture of a medicament for the prevention or treatment of conditions associated to/caused by deficient angiogenesis or conditions beneficing from increased angiogenesis.

3. The use as claimed in claim 2, wherein said peptide has an amino acid sequence consisting of any one of SEQ ID Nos. 2, 3, 9, 10, 13, 14, 15, 16, 17, 18, or a conservative variant thereof.

4. The use as claimed in claim 2 or 3, wherein said medicament is for use in the treatment of ischemic diseases, arterial diseases, cerebrovascular diseases, ulcers, acute and chronic cutaneous wounds, bone and dental pulp loss and in the prevention of spontaneous abortion.

5. The use as claimed in claim 4, wherein said ulcers are preferably selected from gastic and duodenal ulcers.

6. The use as claimed in claim 4, wherein said ischemic diseases are preferably selected from ischemic heart disease, myocardial infarction, acute myocardial infarction, myocardosis, cardiomyopathy, angina pectoris and unstable angina.

7. The use as claimed in claim 4, wherein said arterial diseases are preferably selected from coronary arteriosclerosis, heart failure, arteriosclerosis obliterans (ASO), Berger's disease, vascular injury, arterial embolism, arterial thrombosis, arterial occlusion of the organ, and aneurysm.

8. The use as claimed in claim 4, wherein said cerebrovascular diseases are preferably selected from cerebrovascular occlusion, cerebral infarction, cerebral thrombosis, cerebral embolism, stroke, cerebral hemorrhage, moyamoya disease, cerebrovascular dementia, Alzheimer type dementia, sequela of cerebral hemorrhage, and sequela of cerebral infarction.

9. The use as claimed in claim 4, wherein said spontaneous abortion is recurrent spontaneous abortion.

10. The use as claimed in claim 2 or 3, wherein said medicament is for use as adjuvant therapy in assisted reproduction technology.

11. A pharmaceutical composition comprising (i) a peptide, or derivative thereof, having an amino acid sequence with a length equal to or lower than 30 amino acids and comprising any one of SEQ ID Nos. 2, 3, 9, 10, 13, 14, 15, 16, 17, 18, or a conservative variant thereof, and (ii) at least one pharmaceutically acceptable excipient.

12. A polynucleotide that codes for a peptide, or derivative thereof, having an amino acid sequence with a length equal to or lower than 30 amino acids and comprising any one of SEQ ID Nos. 2, 3, 9, 10, 13, 14, 15, 16, 17, 18, or a conservative variant thereof.

13. A peptide having length equal to or lower than 30 amino acids, and comprising any one of the SEQ ID No. 9, 10, 13, 14, 15, 16, 17, or 18.

14. A peptide having an amino acid sequence consisting of any one of SEQ ID No. 9, 10, 13, 14, 15, 16, 17, or 18.